Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic

Pain

Volumn 152, Issue 4, 2011, Pages 878-887

  Hough, Lindsay B ^a   Nalwalk, Julia W ^a   Yang, Jun ^a   Conroy, Jennie L ^a   Vanalstine, Melissa A ^a,g   Yang, Weizhu ^b   Gargano, Joseph ^c   Shan, Zhixing ^c   Zhang, Shao Zhong ^c   Wentland, Mark P ^c   Phillips, James G ^d   Knapp, Brian I ^e   Bidlack, Jean M ^e   Zuiderveld, Obbe P ^f   Leurs, Rob ^f   Ding, Xinxin ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c Rensselaer Polytechnic Institute   (United States)

^d Curragh Chemistries   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

^g ADELPHI UNIVERSITY   (United States)

Author keywords

Analgesia; Cytochrome P450; Improgan; Nonopioid; Opioid; Pain

Indexed keywords

ANALGESIC AGENT; BRAIN ENZYME; CC12; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; ENZYME INHIBITOR; FLUCONAZOLE; IMPROGAN; MICONAZOLE; MW06 25; N METHYLSULFONYL 6 (2 PROPARGYLOXYPHENYL)HEXANAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BRAIN STEM; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

14-ALPHA DEMETHYLASE INHIBITORS; AMIDES; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; BRAIN; CELL LINE, TRANSFORMED; CIMETIDINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICONAZOLE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, HISTAMINE H3; SULFIDES; TIME FACTORS; TRITIUM;

EID: 79953061202     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2011.01.001     Document Type: Article

References (50)

1. A. Bhardwaj, F.J. Northington, J.R. Carhuapoma, J.R. Falck, D.R. Harder, R.J. Traystman, and R.C. Koehler P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-d-aspartate Am J Physiol Heart Circ Physiol 279 2000 H1616 H1624
2. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem Pharmacol 22 1973 3099 3108
3. J. Cleary, G. Mikus, A. Somogyi, and F. Bochner The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model J Pharmacol Exp Ther 271 1994 1528 1534 (Pubitemid 24382667)
4. J.L. Conroy, C. Fang, J. Gu, S.O. Zeitlin, W. Yang, M.A. VanAlstine, J.W. Nalwalk, P.J. Albrecht, J.E. Mazurkiewicz, A. Snyder-Keller, Z. Shan, S. Zhang, M.P. Wentland, M. Behr, B.I. Knapp, J.M. Bidlack, O.P. Zuiderveld, R. Leurs, X. Ding, and L.B. Hough Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling Nat Neurosci 13 2010 284 286
5. L.A. Crane, and S.D. Glick Simple cannula for repeated intracerebral drug administration in rats Pharmacol Biochem Behav 10 1979 799 800 (Pubitemid 9214809)
6. C.L. Crespi, V.P. Miller, and B.W. Penman Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450 Anal Biochem 248 1997 188 190 (Pubitemid 27218241)
7. F.E. D'Amour, and D.L. Smith A method for determining loss of pain sensation J Pharmacol Exp Ther 72 1941 74 79
8. N.B. Eddy, and D. Leimbach Synthetic analgesics, II Dithienylbutenyl and dithienylbutylamines J Pharmacol Exp Ther 107 1953 385 393
9. N.C. Gehani, J.W. Nalwalk, R.K. Razdan, B.R. Martin, X. Sun, M. Wentland, M.E. Abood, and L.B. Hough Significance of cannabinoid CB(1) receptors in improgan antinociception J Pain 8 2007 850 860 (Pubitemid 350008123)
10. J.R. Graybill, and P.C. Craven Antifungal agents used in systemic mycoses Activity and therapeutic use. Drugs 25 1983 41 62
11. M.M. Heinricher, J.J. Maire, D. Lee, J.W. Nalwalk, and L.B. Hough Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor J Neurophysiol 104 2010 3222 3230
12. T.K. Ho, F.S. LaBella, and C. Pinsky Opiate properties of SKF 525A Can J Physiol Pharmacol 56 1978 550 554 (Pubitemid 8394585)
13. L.B. Hough Improgan-like analgesics: a family of compounds derived From histamine antagonists Med Chem Res 13 2004 78 87 (Pubitemid 39421028)
14. L.B. Hough, J.W. Nalwalk, Y. Chen, A. Schuller, Y. Zhu, J. Zhang, W.M.P.B. Menge, R. Leurs, H. Timmerman, and J.E. Pintar Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice Brain Res 880 2000 102 108
15. L.B. Hough, J.W. Nalwalk, W.M. Menge, R. Leurs, and H. Timmerman Significance of GABAergic systems in the action of improgan, a nonopioid analgesic Life Sci 68 2001 2751 2757 (Pubitemid 32455679)
16. 3H]cimetidine binding, is an improgan antagonist Neuropharmacology 52 2007 1244 1255 (Pubitemid 46527700)
17. L.B. Hough, J.W. Nalwalk, R. Stadel, H. Timmerman, R. Leurs, B.C. Paria, X. Wang, and S.K. Dey Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors J Pharmacol Exp Ther 303 2002 314 322
18. J.J. Iliff, J. Jia, J. Nelson, T. Goyagi, J. Klaus, and N.J. Alkayed Epoxyeicosanoid signaling in CNS function and disease Prostaglandins Other Lipid Mediat 91 2010 68 84
19. C.K. Kuo, N. Hanioka, Y. Hoshikawa, K. Oguri, and H. Yoshimura Species difference of site-selective glucuronidation of morphine J Pharmacobiodyn 14 1991 187 193
20. T. Lehman, and G.R. Peterson Naloxone-reversible analgesic action of SKF 525-A in mice Psychopharmacology (Berl) 59 1978 305 308 (Pubitemid 9089683)
21. B.Y. Li, J.W. Nalwalk, J.M. Finkel, S.D. Glick, and L.B. Hough SKF92374, a cimetidine analog, produces mechanical and thermal antinociception in the absence of motor impairment Analgesia 3 1997 15 20
22. 4 receptor agonist J Pharmacol Exp Ther 314 2005 1310 1321 (Pubitemid 41205997)
23. S. Miksys, and R.F. Tyndale The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics Drug Metab Rev 36 2004 313 333 (Pubitemid 38802491)
24. S. Miksys, and R.F. Tyndale Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition Neuropsychopharmacology 34 2009 634 640
25. J.I. Mobarakeh, J.W. Nalwalk, T. Watanabe, S. Sakurada, M. Hoffman, R. Leurs, H. Timmerman, I. Silos-Santiago, K. Yanai, and L.B. Hough Improgan antinociception does not require neuronal histamine or histamine receptors Brain Res 974 2003 146 152 (Pubitemid 36549228)
26. J.W. Nalwalk, K. Svokos, and L.B. Hough Cannabinoid-improgan cross-tolerance: improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB(1) receptor Eur J Pharmacol 549 2006 79 83 (Pubitemid 44441266)
27. J.W. Nalwalk, K. Svokos, O. Taraschenko, R. Leurs, H. Timmerman, and L.B. Hough Activation of brain stem nuclei by improgan, a nonopioid analgesic Brain Res 1021 2004 248 255 (Pubitemid 39165802)
28. D.R. Nelson, D.C. Zeldin, S.M. Hoffman, L.J. Maltais, H.M. Wain, and D.W. Nebert Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants Pharmacogenetics 14 2004 1 18 (Pubitemid 38183957)
29. P.R. Ortiz de Montellano Cytochrome P450: structure, mechanism, and biochemistry 2005 Kluwer Academic/Plenum Publishers New York
30. D.M. Otto, C.J. Henderson, D. Carrie, M. Davey, T.E. Gundersen, R. Blomhoff, R.H. Adams, C. Tickle, and C.R. Wolf Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis Mol Cell Biol 23 2003 6103 6116 (Pubitemid 37013089)
31. A.L. Parkhill, and J.M. Bidlack Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor Eur J Pharmacol 451 2002 257 264 (Pubitemid 35254028)
32. G. Paxinos, and K.B.J. Franklin The mouse brain in stereotaxic coordinates 2001 Academic Press San Diego
33. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates 1998 Academic Press Sydney
34. X. Peng, J.R. Carhuapoma, A. Bhardwaj, N.J. Alkayed, J.R. Falck, D.R. Harder, R.J. Traystman, and R.C. Koehler Suppression of cortical functional hyperemia to vibrissal stimulation in the rat by epoxygenase inhibitors Am J Physiol Heart Circ Physiol 283 2002 H2029 H2037
35. R.J. Roman P-450 metabolites of arachidonic acid in the control of cardiovascular function Physiol Rev 82 2002 131 185 (Pubitemid 34654217)
36. K.W. Sellers, C. Sun, C. Diez-Freire, H. Waki, C. Morisseau, J.R. Falck, B.D. Hammock, J.F. Paton, and M.K. Raizada Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat FASEB J 19 2005 626 628 (Pubitemid 40471266)
37. A.L. Shen, K.A. O'Leary, and C.B. Kasper Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase J Biol Chem 277 2002 6536 6541 (Pubitemid 34968452)
38. A.A. Spector Arachidonic acid cytochrome P450 epoxygenase pathway J Lipid Res 50 2009 S52 S56
39. A.A. Spector, and A.W. Norris Action of epoxyeicosatrienoic acids on cellular function Am J Physiol Cell Physiol 292 2007 C996 C1012
40. M. Spiecker, and J.K. Liao Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids Arch Biochem Biophys 433 2005 413 420 (Pubitemid 39592795)
41. 3[H]-cimetidine to a heme-containing protein in rat brain Drug Metab Dispos 36 2008 614 621 (Pubitemid 351397988)
42. K. Stark, M. Dostalek, and F.P. Guengerich Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide FEBS J 275 2008 3706 3717
43. M. Terashvili, L.F. Tseng, H.E. Wu, J. Narayanan, L.M. Hart, J.R. Falck, P.F. Pratt, and D.R. Harder Antinociception produced by 14,15- epoxyeicosatrienoic acid is mediated by the activation of {beta}-endorphin and Met-enkephalin in the rat ventrolateral periaqueductal gray J Pharmacol Exp Ther 326 2008 614 619
44. C.W. Vaughan, S.L. Ingram, M.A. Connor, and M.J. Christie How opioids inhibit GABA-mediated neurotransmission Nature 390 1997 611 614 (Pubitemid 28016195)
45. M.H. Wang, E. Brand-Schieber, B.A. Zand, X. Nguyen, J.R. Falck, N. Balu, and M.L. Schwartzman Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors J Pharmacol Exp Ther 284 1998 966 973 (Pubitemid 28130824)
46. H. Watanabe, J. Vriens, J. Prenen, G. Droogmans, T. Voets, and B. Nilius Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels Nature 424 2003 434 438 (Pubitemid 36917492)
47. L. Wu, J. Gu, H. Cui, Q.Y. Zhang, M. Behr, C. Fang, Y. Weng, K. Kluetzman, P.J. Swiatek, W. Yang, L. Kaminsky, and X. Ding Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450 J Pharmacol Exp Ther 312 2005 35 43 (Pubitemid 40096450)
48. K. Yamaura, D. Gebremedhin, C. Zhang, J. Narayanan, K. Hoefert, E.R. Jacobs, R.C. Koehler, and D.R. Harder Contribution of epoxyeicosatrienoic acids to the hypoxia-induced activation of Ca2+ -activated K+ channel current in cultured rat hippocampal astrocytes Neuroscience 143 2006 703 716 (Pubitemid 44751362)
49. C. Yokoyama, F. Shinjo, T. Yoshimoto, S. Yamamoto, J.A. Oates, and A.R. Brash Arachidonate 12-lipoxygenase purified from porcine leukocytes by immunoaffinity chromatography and its reactivity with hydroperoxyeicosatetraenoic acids J Biol Chem 261 1986 16714 16721 (Pubitemid 17000861)
50. D.C. Zeldin Epoxygenase pathways of arachidonic acid metabolism J Biol Chem 276 2001 36059 36062